SCOTT SPRINGER: Open Payments
NPI 1154075018 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$21,699 in 95 payments from 9 companies in 2025. Trend: 2023 $38,428 · 2024 $30,846 · 2025 $21,699
Speaker / faculty: $9,185Consulting: $6,013Travel & lodging: $3,789Food & beverage: $2,712
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $11,032 |
| Gilead Sciences, Inc. | 29 | $6,411 |
| Ipsen Biopharmaceuticals, Inc | 9 | $2,440 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $1,052 |
| Novo Nordisk Inc | 4 | $273 |
| GlaxoSmithKline, LLC. | 1 | $250 |
| Madrigal Pharmaceuticals | 9 | $202 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Orexo US, Inc. | 1 | $16 |
Products named: MAVYRET, Epclusa, IQIRVO, XIFAXAN, REZDIFFRA, Biktarvy, Wegovy, UBRELVY.
Industry payments across NY — which companies pay providers there.
